at our institution, was $1.8 million in While some patients require PPI therapy, many could control their symptoms with a histamine H 2
|
|
- Violet Patrick
- 7 years ago
- Views:
Transcription
1 A Practice-Based Approach for Converting from Proton Pump Inhibitors to Less Costly Therapy CASE REPORT LINDA M. LUCAS, MD MARTHA S. GERRITY, MD, PhD THOMAS ANDERSON, MD Department of Veterans Affairs Medical Center Oregon Health Sciences University Portland, Ore Eff Clin Pract. 2001;4: CONTEXT. Projected cost for lansoprazole, the formulary proton pump inhibitor () at our institution, was $1.8 million in While some patients require therapy, many could control their symptoms with a histamine -receptor antagonist blocker ( blocker) at a much lower cost. OBJECTIVE. To evaluate a practice-based approach to converting patients from s to blockers. DESIGN. Before after study. SETTING. Portland Veterans Affairs Primary Care Clinics. INTERVENTION. We developed guidelines and educated clinicians about the use of s and blockers. To help physicians convert appropriate patients from s to blockers, we gave them a list of their patients receiving s, form letters for patients explaining the conversion, and structured prescription forms. Patient lists and reminders, as well as feedback on institutional performance, were sent to clinicians during the intervention period. OUTCOME MEASURES. Number of and prescriptions per enrollee and pharmacy costs. RESULTS. The average number of prescriptions per enrollee at our institution decreased from 0.39 in the 9 months before the intervention to 0.27 in the 9 months after the intervention. The associated pharmacy costs decreased from an average of $43 to $28 per enrollee per quarter, a difference of $15 or a savings of $80,000 per quarter. Accounting for the decrease in medication prices during the study, this difference was $11 per patient per quarter, corresponding to a savings of about $60,000 per quarter. With respect to the conversion process, more than 70% of clinicians felt the intervention had a big impact on how they prescribed s and blockers. Eighty-two percent of clinicians converted patients from s to blockers during clinic time; 56% did so during administrative time. Overall, more clinicians considered the intervention to be helpful rather than a hassle. CONCLUSIONS. The number of prescriptions decreased during the intervention and was sustained at least three quarters afterward. This low-intensity, practicebased intervention may serve as a model for other health care systems. Faced with a major budget crisis, the hospital administration at the Portland Veterans Affairs (VA) asked the medical service to find ways to lower total costs while maintaining or improving patient care. One target was to reduce the use of Edited by Steven Woloshin, MD, MS This paper is available at ecp.acponline.org American College of Physicians American Society of Internal Medicine 263
2 expensive medications. An obvious first choice was our use of proton pump inhibitors (s), which had a projected cost of about $1.8 million for Unlike other medications, s are primarily used to control symptoms rather than to prevent morbidity or mortality. Our goal was to have clinicians use the least costly drug regimen to control symptoms and prevent the complications of acid peptic disease. To do so, we developed guidelines for appropriate, cost-sensitive use of s and implemented a process that made conversion from s to histamine -receptor antagonists ( blockers) easy for clinicians and patients. To evaluate how well our conversion process worked, we compared the number of prescriptions for s and blockers filled and associated pharmacy costs before and after the intervention. Setting Methods The project took place in the two Portland VA Primary Care Clinics (Portland, Oregon; Vancouver, Washington). Each primary care clinic has a group practice manager and weekly practice meetings. The Portland site has 30 clinicians with 14,000 patients, and the Vancouver site has 5 clinicians with 4500 patients. There were 43 internal medicine housestaff linked with 17 staff physicians at the Portland site, and 6 housestaff linked with 4 staff physicians at the Vancouver site. Attending physicians were responsible for overseeing the conversion process for housestaff. Our VA has a restricted formulary; lansoprazole is our formulary. Lansoprazole initially cost $1.65 per pill (for either a 15- or 30-mg tablet). In November 1999, the price was reduced to $1.31 per pill and in February 2000, to $1.21 per pill. Omeprazole, our nonformulary, accounted for less than 10% of total use and cost $1.90 for a 20-mg capsule or $3.00 for a 40-mg capsule. Only patients with documented side effects from lansoprazole can receive omeprazole. Our formulary blocker was ranitidine 150 mg, which cost $0.50 per pill until December 1998 when the price was reduced to $0.03 per pill. About 10% of patients were receiving cimetidine or famotidine because of side effects from ranitidine. Guideline Development A multidisciplinary group (general internists, a clinical pharmacist, and gastroenterologists) reviewed the literature to develop guidelines for the use of s, particularly for symptoms of chronic gastroesophageal reflux disease (GERD). Acid suppression is recommended for chronic GERD at the lowest dose needed to control symptoms. 1 While lifestyle changes and antacid use may suffice in the 20% of patients with mild reflux, those with more symptomatic GERD require therapy based on severity of symptoms, endoscopic disease, or clinical complications. Among patients with grade 1 or 2 erosive esophagitis (single or multiple erosions on single or multiple esophageal folds), 50% to 70% were free from recurrences at 1 year when treated with ranitidine at doses of 150 mg two to three times daily. 2 4 Symptomatic and endoscopic disease recurred more frequently with ranitidine than with omeprazole when more severe (grades 4 and 5) disease, defined as esophageal ulcers, stricture, or Barrett s epithelium, was being treated. 1 2 Disease severity is not known in patients treated empirically. From local standards of care and literature review, guidelines were developed for our institution (Figure 1). Conversion Process We based our intervention on the PRECEDE model for changing clinician behavior 5 and the literature on local opinion leaders. 6, 7 The PRECEDE model consists of three strategies: predisposing (guidelines, clinician education, and buy-in ), enabling (patient lists, special prescriptions, and patient letters), and reinforcing (individual and practice-level feedback). The model suggests that using all three strategies increases the likelihood of behavior change. We introduced the issue of practice-based conversion from s to less costly therapy at regularly scheduled primary care group meetings. A local gastroenterologist met with primary care providers to discuss cost-effective treatment of chronic GERD. The guidelines were subsequently distributed to clinicians between January and March Our formal conversion program to facilitate change in clinical practice started in July We used the pharmacy database to identify all patients with active prescriptions, the details of the prescription, (dose, expiration date), and the clinician who wrote the prescription. We sent each clinician a cover letter, a list of their patients who had active prescriptions (regardless of who had written the prescription), and the guideline. Clinicians were asked to review the list of their patients with active prescriptions and convert appropriate patients, on the basis of the guidelines, to blockers. Patient lists for the residents were given to their linked clinic staff for review. The cover letter also encouraged providers to seek help from the clinical pharmacists for problems. Clinicians could make these changes during administrative time or could review patients use of s as they were seen in the clinic over the next 6 months. To make this process easier, we also provided the physicians with a Dear Patient form letter, which 264 Effective Clinical Practice November/December 2001 Volume 4 Number 6
3 GENERAL INFORMATION Cost: Lansoprazole 15 or 30 mg capsule: $1.65/capsule Ranitidine 150 mg tablet: $0.03 There is no advantage to lansoprazole 15 mg BID (cost = $3.30/day) over 30 mg QD. Step Down : Patient on BID lansoprazole Step down to QD. Patient on QD lansoprazole Step down to high-dose ranitidine (300 mg BID). (Because of post acid rebound, initial step to 300 mg BID may be more effective than to 150 mg BID). SHORT-TERM USE (Maximum 60 days) 1. Initial empiric Rx for GERD, noncardiac chest pain as a therapeutic trial, ENT symptoms suspected to be due to GERD, such as chronic cough or hoarseness. Many patients will do well with ranitidine 300 mg BID and lifestyle modifications. If first approach is taken, after 8 weeks of therapy, an attempt to step down to ranitidine 300 mg BID must be undertaken. 2. Peptic ulcer disease (PUD) with or without H. pylori. 3. Exceptions to the 60-day limitation: a. During course of endoscopic variceal therapy (3 months after therapy). b. Therapeutic trial in GERD-related ENT symptoms (4 months maximum). CHRONIC USE 1. GERD (including GERD-related ENT symptoms) IF a. Frequent GERD symptoms (near daily), despite regular use of high-dose blocker. b. History of esophageal ulcer or stricture (very strong evidence-based recommendation). c. Barrett s (high-dose blocker Rx may also be appropriate if symptoms are well controlled). 2. NSAIDs-induced gastric ulcer disease in patients who must remain on NSAIDs. a. Ranitidine 300 mg BID is effective; VISN guideline recommends first line. b. s are considered, by some, to be the most effective at prevention of recurrence. c. Misoprostol is effective, but not well tolerated; restricted to 8-week use in elderly patients with active gastritis or PUD and who require ongoing NSAID treatment. 3. Hypersecretory states such as Zollinger-Ellison syndrome. BID DOSING SHORT-TERM USE 1. Initial therapy of complications of GERD, or PUD: upper GI bleed due to PUD, esophageal ulcer/stricture. Reassess after 8 weeks for possible dose reduction. 2. As part of initial H. pylori regimen. CHRONIC USE 1. GERD unrelieved by QD (strongly consider elective EGD). REFERRAL FOR ENDOSCOPY IN GERD 1. Transport dysphagia absolute indication. 2. History of Barrett s with dysplasia. Refer to GI and follow GI recommendations. 3. Consider EGD a. > 5-year history of GERD requiring ongoing medical management. b. GERD requiring BID dosing. c. Failure of high-dose blocker to control symptoms. (Empiric treatment with maintenance may be appropriate.) FIGURE 1. Guidelines for use of proton pump inhibitors (s) (lansoprazole). This guideline was distributed to clinicians as part of the intervention. BID = twice daily; EGD = esophagogastroduodenoscopy; ENT = ear, nose, and throat; GERD = gastroesophageal reflux disease; GI = gastrointestinal; QD = every day; VISN = Veterans Integrated Service Networks. explained the change to blockers and encouraged patients to call a dedicated phone number to talk with a clinical pharmacist if they had questions, and several prescription forms. Copies of the form letters and the prescription forms were available in all outpatient clinic areas for providers during the conversion process. To reinforce change, in October 1999 we gave providers a second list of their patients who were receiving s. The cover letter reminded them to continue the conversion process. Several s were sent to providers during the summer and fall showing the institutional results of the conversion program and reminding providers to continue the process. Evaluation Plan Prescribing Trends To assess the impact of our intervention, we measured the number of prescriptions for s and blockers per enrollee and their associated costs from April 1998 Effective Clinical Practice November/December 2001 Volume 4 Number 6 265
4 through June This time frame gave us three quarters of preintervention data, three quarters of data during the intervention, and three quarters of postintervention data. To summarize the effect, we averaged the number of prescriptions filled per enrollee and the cost per enrollee for the three preintervention quarters and the three postintervention quarters. We used the number of prescriptions filled per enrollee to control for an increase in prescriptions resulting from a growing number of patients using our primary care clinics. We used our pharmacy database to identify the number of and blocker prescriptions filled and associated costs each quarter. Prescriptions included all durations up to our maximum of 90 days. To learn the number of primary care enrollees each quarter, we used our administrative database to identify patients with at least one primary care visit at the Portland VA. Unlike HMOs, the VA does not receive monthly premiums from members. Instead, it tracks the number of individuals who use VA resources each fiscal year. Therefore, we defined enrollees as active VA users (i.e., patients with at least one primary care visit during the quarter) and used the terms patient and enrollee interchangeably. A decrease in the cost of lansoprazole during the study complicated our attempt to estimate the effect of the intervention on costs. To estimate the change in costs per patient attributable to our intervention (rather than price changes), we calculated the cost of s per patient for each quarter assuming a constant price for lansoprazole. Specifically, we calculated the cost per prescription filled, assuming the lowest price of $1.21 per pill ($310,000/3249 prescriptions = $95/prescription). We multiplied $95 by the average number of prescriptions filled per patient for the three preintervention quarters (0.39 prescriptions per patient) and the three postintervention quarters (0.27 prescriptions per patient). Clinician Evaluation of the Conversion Process Providers were surveyed in March 2000 to identify the components of the conversion process that had the greatest impact on their use of s, how frequently they used a component, and whether a component was a hassle or helpful. They were asked to rate each component on a scale of 0 (little impact) to 5 (big impact) and on a scale of 0 (hassle) to 5 (helpful). Providers also rated the frequency with which they used a process to make the conversion on a scale of 0 (rarely) to 5 (frequently). Clinicians responses were dichotomized into having an impact (score 3), being a hassle (score 1) or helpful (score 4), and frequent use (score 3). We used percentages to describe the clinicians responses to the survey items. Prescribing Trends Results Figure 2 and Table 1 display the trends in and blocker prescriptions filled during the preintervention (April December 1998), intervention (January September 1999), and postintervention (October 1999 June 2000) periods. In the preintervention period, s accounted for approximately 55% of all prescriptions for s and blockers. This dropped to 40% after the intervention. The number of prescriptions filled averaged 3479 per quarter with a cost of about $385,000 per quarter (9.9% of total outpatient pharmacy costs) for the three preintervention quarters (Table 1). By April June 1999, after meetings with primary care providers to develop guidelines, the number of prescriptions began to decrease to 3274 per quarter with a cost of about $387,000 (8.8%). For the three postintervention quarters, the total number of prescriptions filled at our institution averaged 2959 per quarter, with a cost of about $305,000 per quarter (6.7%). The number of blocker prescriptions filled averaged 2900 per quarter for the three preintervention quarters and increased to an average of 4391 per quarter for the three postintervention quarters. Although blocker prescriptions increased, our cost substantially decreased because of a significant price reduction for generic ranitidine from $0.50 per pill to $0.03 per pill in late December Because the number of primary care patients increased during our study period, we calculated the number of prescriptions filled per patient and cost per patient for s and blockers (Table 1). Figure 2 displays the trends in quarterly prescriptions per patient and cost per patient for s and blockers. On average, 0.39 prescriptions were filled per patient before the intervention and 0.27 after the intervention. Our average cost per patient for s was $43 for the three preintervention quarters and $28 after the intervention for a quarterly average cost savings of $15 per enrollee (35% reduction) or yearly savings of $60 per patient. To control for decreases in the cost of lansoprazole, we estimated the average quarterly cost per patient using the cost from April June 2000 when lansoprazole was at its lowest price ($1.21 per pill). Had the lansoprazole price been this consistently low throughout the study, the average pre- and postintervention costs per patient per quarter would have been $37 and $26, respectively, for a savings of $11 per enrollee per quarter (30% reduction) or $44 per patient per year. Because we used the lowest price of lansoprazole, this estimate of the savings is conservative. 266 Effective Clinical Practice November/December 2001 Volume 4 Number 6
5 Clinician Evaluation of the Conversion Process Twenty-three (66%) providers returned the survey. Fifty-two percent of these respondents spent more than 5 half-days per week in clinic. More than 70% felt that the conference with the gastroenterologist, written guidelines, list of providers patients on s, and feedback about expenditures had a big impact on their behavior. In general, more clinicians reported that the components of the intervention were helpful than those who reported them to be a hassle (Table 2). Thirty-eight percent of clinicians felt that the prescription form was a hassle versus 24% who felt it was helpful, and 35% felt the list of their patients receiving s was a hassle versus 39% who felt it was helpful. Eighty-three percent of clinicians reported that they frequently changed patients from s to blockers while seeing them in clinic, yet 56% also changed prescriptions for patients during administrative time. Few providers (13%) enlisted the help of the Quarterly Number of Prescriptions per Enrollee Preintervention Intervention Postintervention Blocker Apr Jun Jul Sept Oct Dec Jan Mar Apr Jun Jul Sept Oct Dec Jan Mar Apr Jun Quarterly Cost per Enrollee, $ Blocker 0 Apr Jun Jul Sept Oct Dec Jan Mar Apr Jun Jul Sept Oct Dec Jan Mar Apr Jun Blocker ($/pill) ($/pill) FIGURE 2. Average number and cost of histamine -receptor antagonist blocker ( ) and proton pump inhibitor () prescriptions filled by quarter. Effective Clinical Practice November/December 2001 Volume 4 Number 6 267
6 TABLE 1 Proton Pump Inhibitor and Histamine -Receptor Antagonist Blocker ( blocker) Prescriptions Filled and Associated Pharmacy Costs by Quarter* PHARMACY DATA PREINTERVENTION INTERVENTION POSTINTERVENTION APRIL JUNE 1998 JULY SEPT 1998 OCT DEC 1998 JAN MAR 1999 APRIL JUNE 1999 JULY SEPT 1999 OCT DEC 1999 JAN MAR 2000 APRIL JUNE 2000 Numbers of patients receiving primary care ,126 12,364 Outpatient prescriptions filled blocker per enrollee blocker per enrollee Outpatient pharmacy costs (% of total pharmacy cost) $367 (10.1%) $377 (10.0%) $412 (9.6%) $412 (9.8%) $387 (8.8%) $356 (7.5%) $309 (6.8%) $295 (6.5%) $310 (6.7%) blocker $55 (1.5%) $54 (1.4%) $63 (1.5%) $39 (0.9%) $25 (0.6%) $25 (0.5%) $26 (0.6%) $19 (0.4%) $21 (0.5%) Total pharmacy cost $3631 $3752 $4280 $4186 $4418 $4766 $4520 $4534 $4602 Outpatient pharmacy costs per patient $42 $42 $46 $43 $41 $38 $32 $26 $25 blocker $6 $6 $7 $4 $3 $3 $3 $2 $2 Sum and blocker $48 $49 $53 $47 $44 $40 $34 $28 $27 * = proton pump inhibitor. Costs are in thousands of dollars (U.S.). Sum may differ due to rounding. clinical pharmacist. The prescription form and the electronic prescription process for documenting the reason why the must be used were used frequently by clinicians 57% and 65%, respectively. Only one provider reported an adverse outcome from stepping down to a blocker (mental status changes in an elderly patient on multiple medications), and one reported that the process generated a letter to a member of Congress. The clinical pharmacist reported that fewer than 10 patients called to discuss the change in medication. Discussion The overall number of prescriptions filled decreased, and this decrease was sustained for three quarters after the conversion process. Thus, the overall cost of s decreased at a time when total prescriptions 268 Effective Clinical Practice November/December 2001 Volume 4 Number 6
7 TABLE 2 Clinicians Perceptions of the Components of the Intervention* COMPONENT prescription form List of clinicians patients receiving s Feedback about group expenditures for s Form letter for patients explaining step-down therapy Written guidelines HASSLE 38% 35% 26% 24% 14% HELPFUL 24% 39% 56% 43% 45% * = proton pump inhibitor. Components were rated on a scale of 0 (hassle) to 5 (helpful). Hassles were given ratings of 0 to 1, and helpful was given ratings of 4 to 5. The percentage is based on the number of responses to each component. The number of responses varied from 21 to 23. filled and pharmacy costs increased. We estimated a savings of $11 (30% reduction) to $15 (35%) per patient per quarter. In contrast, national sales of antiulcer medications remained among the top three revenue-producing drugs, and omeprazole was the highest revenue-producing drug, doubling its sales from 1998 to In Oregon, Blue Cross/Blue Shield reported per-member, per-quarter costs of $1.07 in October December 1998, which increased slowly to $1.92 in April June (Note: These figures encompass members of all ages, including children.) The cost of blockers per member did not change during the same period (Allen JA. Personal communication). This represents a 79% increase in per-member, per-quarter costs compared with a 30% decrease in per-enrollee, per-quarter costs at the Portland VA. Our savings should continue, since new prescriptions require providers to consider the same guidelines. Our evaluation has several limitations. First, it is an observational study at a single VA Medical Center. Other factors might have contributed to the decrease in percentage of prescriptions filled. The lack of a control group makes it impossible to know if secular events independent of the intervention might have led to prescription conversions. Although the process and results should be generalizable to health care organizations with similar electronic databases, the study should be replicated to assess generalizability. Second, the effect of the intervention on costs may be confused by decreases in the costs of lansoprazole and increases in the total number of prescriptions filled, so we can only estimate the potential cost savings. However, we took a conservative approach to estimating these savings. Third, we did not calculate the costs of the intervention, including that of the clinical pharmacist s time. However, we did not hire new personnel to implement the intervention. The cost data also do not account for possible extra visits or tests for patients who did poorly with the conversion. Finally, we did not assess appropriateness of the conversions, patient satisfaction, or clinical outcome. Another study suggests that patients are concerned about changing from an effective therapy like a to other drugs, but would change if their provider suggested it. 9 In the fall of 1999, our pharmacists tracked 142 patients converted from s to blockers. They found that 44 patients (31%) were restarted on s within 6 months after conversion to blockers (Hirokane G. Personal communication). Clinicians and pharmacists at our institution reported that the only patient problems encountered were increased symptoms (which responded promptly when the was restarted) and one potential adverse drug reaction. Providers surveyed found that consensus on appropriate use (conference with a gastroenterologist and written guidelines) had a big impact on their clinical management, as did providing them with populationbased information (lists of their patients on s, feedback about their patients on s, and institutional expenditures) during the process. They also reported that the lists and prescription form were a hassle. We suspect that clinicians viewed this intervention as one more thing they should do in the course of their busy practices. This has implications for implementation of this intervention and other provider-based interventions. Organizations should consider the number and types of changes providers are being requested to make at any one time. The hassle might have prevented our ability to successfully implement the intervention if other major changes were occurring at the same time. This low-intensity intervention that incorporates a population-based approach into the clinicians individual practices appears to be effective and may serve as a model for other health care systems. This approach involves primary care clinicians and gives them the tools to make appropriate decisions for their patients and practice. However, it should not be used at a time when clinicians are being asked to make other changes that might increase their workload. Effective Clinical Practice November/December 2001 Volume 4 Number 6 269
8 Take-Home Points The difference in cost between proton pump inhibitors (s) and histamine -receptor antagonists ( blockers) is considerable. Although some patients require therapy, many could be converted to blockers. We developed guidelines for use of s with input from local experts and clinicians and educated a group of clinicians at two VA primary care clinics. Clinicians were asked to use these guidelines to review a list of their patients on s for possible conversion to blockers. To facilitate these changes, providers were given Dear Patient form letters, prescription forms, ongoing feedback about the results, and regular reminders. The number of prescriptions filled decreased during the intervention and was sustained for 9 months after the intervention, which translated to a quarterly savings of between $11 and $15 per patient per quarter or between about $60,000 to $80,000 per quarter. Clinicians reported that the written guidelines, feedback about group expenditures, and patient form letters were most helpful. This relatively simple approach to changing practice patterns should be tried in other health care organizations. REFERENCES 1. Harris RA, Kupperman M, Richter JE. Prevention of recurrences of erosive reflux esophagitis: a cost-effectiveness analysis of maintenance proton pump inhibition. Am J Med. 1997;102: Vigneri S, Termini R, Leandro G, et al. A comparison of five maintenance therapies for reflux esophagitis. N Engl J Med. 1995;333: Janisch H, Huffemann W, Bouzo M. Cisapride vs. ranitidine in treatment of reflux esophagitis. Hepatogastroenterology. 1998;35: Geldof H, Hazelhoff B, Otten MH. Two different dose regimens of cisapride in treatment of reflux oesophagitis: a doubleblind comparison with ranitidine. Aliment Pharmacol Ther. 1993;7: Green LW, Kreuter MW, Deeds SG, Partridge KB, Bartlett E. Health Education Planning: A Diagnostic Approach. Palo Alto, CA: Mayfield Press; Davis DA, Thomson MA, Oxman AD, Haynes RB. Changing physician performance: a systematic review of the effect of continuing medical education strategies. JAMA. 1995;274: His RG, MacDonald R, Davis WK. Identification of physician educational influentials in small community hospitals. Proc Conference Res Med Educ. 1978; 7: Boath EH, Blenkinsopp A. The rise and rise of proton pump inhibitor drugs: patients perspectives. Soc Sci Med. 1997; 45: Correspondence Linda M. Lucas, MD, Portland VA Medical Center, Division of Hospital and Specialty Medicine, PO Box 1034, Portland, OR 97207; telephone: ; fax: ; Linda.Lucas@med.va.gov. 270 Effective Clinical Practice November/December 2001 Volume 4 Number 6
Gloucestershire Hospitals
TRUST GUIDELINE In the case of hard copies of this policy the content can only be assured to be accurate on the date of issue marked on the document. The Policy framework requires that the policy is fully
More informationGastroesophageal Reflux Disease (GERD) and Barrett s Esophagus (BE)
Gastroesophageal Reflux Disease (GERD) and Barrett s Esophagus (BE) Hashem El-Serag, M.D., M.P.H. Dan L. Duncan Professor of Medicine Chief, Gastroenterology and Hepatology Baylor College of Medicine Houston,
More informationA. Ketorolac*** B. Naproxen C. Ibuprofen D. Celecoxib
1. A man, 66 years of age, with a history of knee osteoarthritis (OA) is experiencing increasing pain at rest and with physical activity. He also has a history of depression and coronary artery disease.
More informationGASTROESOPHAGEAL REFLUX DISEASE (GERD)
GASTROESOPHAGEAL REFLUX DISEASE (GERD) Gastroesophageal reflux disease is a clinical scenario where the gastric or duodenal contents reflux back up into the esophagus. Reflux esophagitis, however, is a
More informationResearch funding was provided by TAP Pharmaceutical Products, Inc.
DOES THE DOSING FREQUENCY OF PROTON PUMP INHIBITORS (PPIs) AFFECT SUBSEQUENT RESOURCE UTILIZATION AND COSTS AMONG PATIENTS DIAGNOSED WITH GASTROESOPHAGEAL REFLUX DISEASE (GERD)? Boulanger L 1, Mody R 2,
More informationImproving Appropriate Use of Proton Pump Inhibitors as Gastrointestinal Prophylaxis in the Hospital Setting
Improving Appropriate Use of Proton Pump Inhibitors as Gastrointestinal Prophylaxis in the Hospital Setting DATE Educating for Quality Improvement & Patient Safety 1 The Team Division CS&E Participants
More informationGastroesophageal Reflux Disease (GERD) Physician Performance Measurement Set
American Gastroenterological Association Institute/Physician Consortium for Performance Improvement Gastroesophageal Reflux Disease (GERD) Physician Performance Measurement Set October 2006 GERD Work Group
More informationTreatments for Barrett s Oesophagus
Treatments for Barrett s Oesophagus Introduction This leaflet describes the various ways in which Barrett s Oesophagus is treated. It has been produced in association with Heartburn Cancer UK (HCUK), a
More information1-800-HRT-BURN. understanding gerd. Is it just a little HEARTBURN. or something more serious? NEW
Do you have GERD? Measure Yourself on the Richter Scale/Acid Test How significant is your heartburn? What are the chances that it is something more serious? If you need a yardstick, here s a simple self-test
More informationDigestive System (continued) Digestive System. Stomach. Peptic Ulcer Disease
Digestive System Digestive System (continued) Responsible for breaking down food, absorbing nutrients, eliminating wastes Alimentary canal Also known as gastrointestinal tract Reaches from mouth to anus
More information6. MEASURING EFFECTS OVERVIEW CHOOSE APPROPRIATE METRICS
45 6. MEASURING EFFECTS OVERVIEW In Section 4, we provided an overview of how to select metrics for monitoring implementation progress. This section provides additional detail on metric selection and offers
More informationNational Digestive Diseases Information Clearinghouse
Barrett s Esophagus National Digestive Diseases Information Clearinghouse U.S. Department of Health and Human Services NATIONAL INSTITUTES OF HEALTH What is Barrett s esophagus? Barrett s esophagus is
More informationBYE-BYE, PPI. A toolkit for deprescribing proton pump inhibitors in EMR-enabled primary care settings
BYE-BYE, PPI. A toolkit for deprescribing proton pump inhibitors in EMR-enabled primary care settings version 1.0 Don t maintain long-term Proton Pump Inhibitor (PPI) therapy for gastrointestinal symptoms
More informationFigure 3: Dysphagia. 14 meets. esophageal. esophageal manometry +/- +/- impedance measurement. structural lesion? no. 19 yes
Figure 3: Dysphagia 1 patient with dysphagia 2 history and physical exam. suggestive of nesophageal etiology? 3 evaluate and treat as as indicated 4 upper GI GI endoscopy with biopsies 15 achalasia, absent
More informationPublic Assessment Report. Pharmacy to General Sales List Reclassification. Nexium Control 20mg Gastro-Resistant Tablets.
Public Assessment Report Pharmacy to General Sales List Reclassification Nexium Control 20mg Gastro-Resistant Tablets (Esomeprazole) EMA Agency number: Pfizer Consumer Healthcare Ltd TABLE OF CONTENTS
More informationBRITTANY N. HARRIS; DONNA S. WEST, RPh, PhD; JILL JOHNSON, PharmD; SONG HEE HONG, PhD; and CINDY D. STOWE, PharmD
CONTEMPORARY SUBJECT Effects on the Cost and Utilization of Proton Pump Inhibitors From Adding Over-the Counter Omeprazole to Drug Benefit Coverage in a State Employee Health Plan BRITTANY N. HARRIS; DONNA
More informationMedical Nutrition Therapy for Upper Gastrointestinal Tract Disorders. By: Jalal Hejazi PhD, MSc.
Medical Nutrition Therapy for Upper Gastrointestinal Tract Disorders By: Jalal Hejazi PhD, MSc. Digestive Disorders Common problem; more than 50 million outpatient visits per year Dietary habits and nutrition
More informationFigure 2: Recurrent chest pain of suspected esophageal origin
Figure 2: Recurrent chest pain of suspected esophageal origin 1 patient with chest pain of suspected esophageal origin 2 history and physical exam. suggestive of n-esophageal etiology? 3 evaluate and treat
More informationInhibit terminal acid secretion from parietal cells by blocking H + /K + - ATPase pump
Chris J. Taylor, Pharm.D., BCPS Clinical Pharmacist Phoenix VA Health Care System Review pharmacology of PPIs Discuss possible association between PPI use and development of the following: Pneumonia (community-acquired
More informationAssociation between Proton Pump Inhibitors and Clostridium difficile
Association between Proton Pump Inhibitors and Clostridium difficile Lauren Petrik and Nicholas Hellebusch, Pharm.D. Candidates 2013, Tatum Mead, Pharm.D. UMKC School of Pharmacy Clostridium difficile,
More informationPATIENTS AND METHODS
symptoms 5. Heartburn is also common and the sufferers attribute symptoms to various lifestyle events, including diet and stress. In all these cases antacid usage is the commonest mode of therapy 6. Antacid
More informationStep-Down Management of Gastroesophageal Reflux Disease
GASTROENTEROLOGY 2001;121:1095 1100 Step-Down Management of Gastroesophageal Reflux Disease JOHN M. INADOMI,*, ROULA JAMAL,, GLEN H. MURATA,, RICHARD M. HOFFMAN,, LAURENCE A. LAVEZO,, JUSTINA M. VIGIL,,
More informationUse of stents in esophageal cancer" Hans Gerdes, M.D. Director, GI Endoscopy Unit Memorial Sloan-Kettering Cancer Center
Use of stents in esophageal cancer" Hans Gerdes, M.D. Director, GI Endoscopy Unit Memorial Sloan-Kettering Cancer Center Features of esophageal cancer Esophageal cancer is an abnormal growth that arises
More informationAmerican Gastroenterological Association Institute Technical Review on the Management of Gastroesophageal Reflux Disease
GASTROENTEROLOGY 2008;135:1392 1413 American Gastroenterological Association Institute Technical Review on the Management of Gastroesophageal Reflux Disease Learning Objectives At the end of this activity,
More informationACTIVELY MANAGED DRUG SOLUTIONS. for maintenance and specialty medication. Actively Managed Drug Solutions is not available in the province of Quebec
ACTIVELY MANAGED DRUG SOLUTIONS for maintenance and specialty medication Actively Managed Drug Solutions is not available in the province of Quebec ARE YOU UNDERESTIMATING THE IMPACT OF CHRONIC DISEASE?
More informationKansas Medical Assistance Programs Retrospective Drug Utilization Review Provider Education and Intervention Program
Program Outcomes Evaluating, Measuring, and Identifying Patient Care Benefits and Cost Reduction Kansas Medical Assistance Programs Retrospective Drug Utilization Review Provider Education and Intervention
More informationThe JPMorgan Chase Prescription Drug Plan Effective January 1, 2010 (CVS Caremark web site version)
The JPMorgan Chase Prescription Drug Plan Effective January 1, 2010 (CVS Caremark web site version) OVERVIEW This Bulletin provides an overview of, as well as detail on changes to, the JPMorgan Chase Prescription
More informationProton pump inhibitors
Proton pump inhibitors This brochure gives you information about acid reflux and some of the prescription medicines commonly used to manage it. You will learn how these medicines compare and get important
More informationNational Digestive Diseases Information Clearinghouse
Gastritis National Digestive Diseases Information Clearinghouse U.S. Department of Health and Human Services NATIONAL INSTITUTES OF HEALTH What is gastritis? Gastritis is a condition in which the stomach
More informationunderstanding GI bleeding
understanding GI bleeding a consumer education brochure American College of Gastroenterology 4900B South 31st Street, Arlington, VA 22206 703-820-7400 www.acg.gi.org American College of Gastroenterology
More informationPotential Savings from Generic Drugs in Upstate New York
T H E F A C T S A B O U T Potential Savings from Generic Drugs in Upstate New York $880 Million in Potential Savings for Upstate New York Counties Finger Lakes Region $141 million Western New York Region
More informationCombined Assessment Program Summary Report. Evaluation of Pressure Ulcer Prevention and Management at Veterans Health Administration Facilities
Department of Veterans Affairs Office of Inspector General Report No. 14-05132-90 Office of Healthcare Inspections Combined Assessment Program Summary Report Evaluation of Pressure Ulcer Prevention and
More informationTurning on the Care Coordination Switch in Rural Primary Care Practices
Turning on the Care Coordination Switch in Rural Primary Care Practices AHRQ Master Contract Task Order #5 HHSA2902007100016I (9/07-11/09) Care Management Plus research at OHSU is supported by funding
More informationThe Minnesota Chlamydia Strategy: Action Plan to Reduce and Prevent Chlamydia in Minnesota Minnesota Chlamydia Partnership, April 2011
The Minnesota Chlamydia Strategy: Action Plan to Reduce and Prevent Chlamydia in Minnesota Minnesota Chlamydia Partnership, April 2011 Section 5: Screening, Treating and Reporting Chlamydia While the information
More informationGastroesophageal Reflux Disease
3702 Timberline Rd 2555 East 13th St Suite 220 Ft.Collins, CO 80525 Loveland, CO 80537 82001 7251 W. 20th St Greeley, CO 80634 4108 Laramie Cheyenne, WY Gastroesophageal Reflux Disease Author(s): Peter
More informationArticles Presented. Journal Presentation. Dr Albert Lo. Dr Albert Lo
* This presentation is prepared by the author in one s personal capacity for the purpose of academic exchange and does not represent the views of his/her organisations on the topic discussed. Journal Presentation
More information2015 Travelers Prescription Drug Plan Blue Cross Blue Shield Plan and United Healthcare Choice Plus Plan
2015 Travelers Prescription Drug Plan Blue Cross Blue Shield Plan and United Healthcare Choice Plus Plan Plan Details, Programs, and Policies Table of Contents Click on the links below to be taken to that
More informationwww.booneinsuranceassociates.com Copyright by BIA 1 MEDICARE MADE SIMPLE BIA 1/14/2016 Boone Insurance Associates Education Guide: New
www.booneinsuranceassociates.com Copyright by 1 MEDICARE MADE SIMPLE Boone Insurance Associates Education Guide: New Today s Agenda 2 About Introduction & History of Medicare Medicare Parts A, B, C, D
More informationAudit of Six Ulcer Treatment Drugs Reimbursed Under the Indiana Medicaid Prescription Drug Program (A-06-92-00007)
c \L.i( #I f: y**.a*, a ; % Q4 t im Wll DEPARTMENT OF HEALTH & HUMAN SERVICES Office of inspector General :, Memorandum ~~flpipqly. Principal Deputy inspector General To Audit of Six Ulcer Treatment Drugs
More informationSecure Messaging Evidence Table
APPENDIX E. Evidence Tables Secure Messaging Evidence Table Health Outcomes Simon, 2011 9 RCT; N=208 patients; 04/09-10/09 Elkjaer, 2010 1 Zhou, 2010 2 Harris, 2009 3 Ralston, 2009 6 Tuil, 2007 4 RCT;
More informationhow to choose the health plan that s right for you
how to choose the health plan that s right for you It s easy to feel a little confused about where to start when choosing a health plan. Some people ask their friends, family, or co-workers for advice.
More informationFormulary Management
Formulary Management Formulary management is an integrated patient care process which enables physicians, pharmacists and other health care professionals to work together to promote clinically sound, cost-effective
More informationNew Anticoagulants and GI bleeding
New Anticoagulants and GI bleeding DR DANNY MYERS MD FRCP(C) CLINICAL ASSISTANT PROFESSOR OF MEDICINE, UBC Conflicts of Interest None I am unbiased in the use of NOAC s vs Warfarin based on risk benefit
More informationReducing Resident Readmissions: The Pierce County Medicaid Nursing Home Collaborative
Reducing Resident Readmissions: The Pierce County Medicaid Nursing Home Collaborative April 2015 Overview The Washington State Department of Social & Health Services (DSHS) and Qualis Health engaged 14
More informationPATIENT REPORTED OUTCOMES IN ESOPHAGEAL DISEASE: AN OPEN SOURCE WEB BASED FRAMEWORK
Northwestern University Feinberg School of Medicine PATIENT REPORTED OUTCOMES IN ESOPHAGEAL DISEASE: AN OPEN SOURCE WEB BASED FRAMEWORK Andrew Gawron, MD, PhD Co-authors: Sherri LaVela, Jane Holl, David
More informationAntimicrobial Stewardship for Hospital Acquired Infection Prevention: Focus on C. difficile infection
Antimicrobial Stewardship for Hospital Acquired Infection Prevention: Focus on C. difficile infection Emi Minejima, PharmD Assistant Professor of Clinical Pharmacy USC School of Pharmacy minejima@usc.edu
More informationDrug Class Review Proton Pump Inhibitors
Drug Class Review Proton Pump Inhibitors Final Report Update 5 May 2009 Update 4: May 2006 Update 3: May 2005 Update 2: April 2004 Update 1: April 2003 Original Report: November 2002 The literature on
More informationBancorp Insurance Medicare Vocabulary
Bancorp Insurance Medicare Vocabulary Advance Beneficiary Notice (ABN) A notice indicating the cost of a service that Medicare might not cover. Accepting Assignment Your Doctor agrees to accept payment
More informationProton Pump Inhibitor Utilization Patterns in Infants
Journal of Pediatric Gastroenterology and Nutrition 45:421 427 # 2007 by European Society for Pediatric Gastroenterology, Hepatology, and Nutrition and North American Society for Pediatric Gastroenterology,
More informationTapered Withdrawal of a Proton Pump Inhibitor to Prevent Rebound Acid-Related Symptoms
Akin Oyalowo CRC Rotation IRB Proposal August 8, 2012 Tapered Withdrawal of a Proton Pump Inhibitor to Prevent Rebound Acid-Related Symptoms A. Study Purpose and Rationale Proton pump inhibitors (PPIs)
More informationRivaroxaban shared care guidelines for the prevention of stroke and embolism in adult patients with nonvalvular atrial fibrillation.
South West Essex Rivaroxaban Shared Care Guideline (SCG) Rivaroxaban shared care guidelines for the prevention of stroke and embolism in adult patients with nonvalvular atrial fibrillation. Introduction
More informationChapter 6 Gastrointestinal Impairment
Chapter 6 Gastrointestinal This chapter consists of 2 parts: Part 6.1 Diseases of the digestive system Part 6.2 Abdominal wall hernias and obesity PART 6.1: DISEASES OF THE DIGESTIVE SYSTEM Diseases of
More informationOutcome of Drug Counseling of Outpatients in Chronic Obstructive Pulmonary Disease Clinic at Thawangpha Hospital
Mahidol University Journal of Pharmaceutical Sciences 008; 35(14): 81. Original Article Outcome of Drug Counseling of Outpatients in Chronic Obstructive Pulmonary Disease Clinic at Thawangpha Hospital
More informationGuidelines for the Development of an Individualized Learning Plan for Pharmacists Working in Primary Care Practice
Guidelines for the Development of an Individualized Learning Plan for Pharmacists Working in Primary Care Practice These Guidelines outline important knowledge, skills, and values for pharmacists working
More informationMedication Safety in Primary Care Practice Translating Research into Practice (MS-TRIP)
Grant Final Report Grant ID: 5R18HS017037 Medication Safety in Primary Care Practice Translating Research into Practice (MS-TRIP) Inclusive Dates: 09/30/07 09/29/10 Principal Investigator: Steven Ornstein,
More informationPeptic Ulcer. Anatomy The stomach is a hollow organ. It is located in the upper abdomen, under the ribs.
Peptic Ulcer Introduction A peptic ulcer is a sore in the lining of your stomach or duodenum. The duodenum is the first part of your small intestine. Peptic ulcers may also develop in the esophagus. Nearly
More informationGastroesophageal Acid Reflux: How to Effectively Eric Crihfield Recognize and Treat This Wide Spread Disease
consumption. Gastroesophageal Acid Reflux: How to Effectively Eric Crihfield Recognize and Treat This Wide Spread Disease Daniel Ryczek Victoria Adams Contributors: Eric Crihfield, MD, PhD, Director of
More informationThe Patient-Centered Medical Home How Does Managed Care Pharmacy Add Value?
The Patient-Centered Medical Home How Does Managed Care Pharmacy Add Value? With heath care reform now being implemented, it is important that managed care pharmacy understand how to provide value for
More informationWhat is Barrett s esophagus? How does Barrett s esophagus develop?
Barrett s Esophagus What is Barrett s esophagus? Barrett s esophagus is a pre-cancerous condition affecting the lining of the esophagus, the swallowing tube that carries foods and liquids from the mouth
More informationThe Benefits of Disease Therapy Management (DTM) for Multiple Sclerosis (MS)
A WHITE PAPER BY The Benefits of Disease Therapy Management (DTM) for Multiple Sclerosis (MS) First-of-its-kind study finds improved outcomes, reduced costs Summer 2010 The Benefits of DTM for Multiple
More informationIndiana University Health
Improving Acute Pain Management for Inpatients Using a Patient-Customized Opioid Tolerance Program Jill Payne, MSN, RN, Director, Surgical Patient Care Division Jim Ryser, MA, LCAC, Program Manager, Pain
More informationHow To Manage Prescription Drug Costs In Workers Compensation
June 2012 Jacob Lazarovic, M.D. Chief Medical Officer, SVP Broadspire Escalating Pharmaceutical Costs in Workers Compensation: One Clinical Solution One Clinical Solution Pharmaceutical (Rx) costs have
More informationNorth Carolina Medicaid Special Bulletin
North Carolina Medicaid Special Bulletin An Information Service of the Division of Medical Assistance Please visit our Web site at www.ncdhhs.gov/dma July 2007 ATTENTION: All Providers Notice of Change
More informationCMAJ JAMC. An evidence-based approach to the management of uninvestigated dyspepsia in the era of Helicobacter pylori
CANADIAN M EDICAL A SSOCIATION J OURNAL J OURNAL DE L ASSOCIATION MÉDICALE CANADIENNE CMAJ JAMC Return to June 13, 2000 Table of Contents An evidence-based approach to the management of uninvestigated
More informationMarch 7, 2014. [Submitted electronically to AdvanceNotice2015@cms.hhs.gov]
March 7, 2014 [Submitted electronically to AdvanceNotice2015@cms.hhs.gov] Centers for Medicare and Medicaid Services Department of Health and Human Services Attention: CMS-4159-P P.O. Box 8013 Baltimore,
More informationShared Care Guideline-Use of Donepezil, Galantamine, Rivastigmine and Memantine in Dementia
Shared Care Guideline-Use of Donepezil, Galantamine, Rivastigmine and Memantine in Dementia Version: 3.0 Ratified by: Medicines Committee Date ratified: 16 th November 2011 Name of originator/author: James
More information10/31/2014. Medication Adherence: Development of an EMR tool to monitor oral medication compliance. Conflict of Interest Disclosures.
Medication Adherence: Development of an EMR tool to monitor oral medication compliance Donna Williams, RN PHN Carol Bell, NP MSN Andrea Linder, RN MS CCRC Clinical Research Nurses Stanford University SOM
More informationGI Bleed. Steven Lichtenstein, D.O. Chief, Division of Gastroenterology Mercy Health System. Director, Endoscopy/GI Lab Mercy Fitzgerald Hospital
October 3, 2015 GI Bleed Steven Lichtenstein, D.O. Chief, Division of Gastroenterology Mercy Health System Director, Endoscopy/GI Lab Mercy Fitzgerald Hospital Clinical Associate Professor of Medicine
More informationPATIENT CENTRIC MODEL P I LOT DATA ANALYSIS R EPORT
PATIENT CENTRIC MODEL P I LOT DATA ANALYSIS R EPORT PREPARED FOR THE ALLIANCE FOR PATIENT MEDICATION SAFETY April 2011 D A V I D A. H O L D F O R D R P H, P H D A S S O C I A T E P R O F E S S O R T I
More informationVA Telehealth Technologies: Rural. VISTA / CPRS For Patient Care: Rural. VA Telehealth Technologies EMR / CPRS Order Entry. Care Coordination: Concept
VISTA / CPRS For Patient Care: Rural VA Telehealth Technologies EMR / CPRS Order Entry VA Telehealth Technologies: Rural Continuity of care for patients across the continuum Focus = Patient & their optimal
More informationUpper Endoscopy (EGD)
Upper Endoscopy (EGD) Appointment Information: Patient Name: MRN: Physician Name: Location: _ For information on Directions, please visit: http://www.brighamandwomens.org/general/directions/directions.aspx
More informationAwareness of the inappropriate use of GI prophylaxis and its cost. Adverse effects of proton pump inhibitor
Understand the indication for stress ulcer/gi prophylaxis Awareness of the inappropriate use of GI prophylaxis and its cost Adverse effects of proton pump inhibitor A. 65yo w/ HTN and ESRD on HD p/w left
More informationS1. Which of the following age categories do you fall into? Please select one answer only. 18-44 years of age. 45-64 years of age. 65-74 years of age
Supplemental Materials Supplemental Methods Patient Survey We are presently conducting a market research study to help us better understand some of the challenges experienced by patients taking anticoagulants
More informationGastroesophageal Reflux Disease (GERD)
GERD Guideline Team Team Leader Joel J Heidelbaugh, MD Family Medicine Team Members R Van Harrison, PhD Medical Education Mark A McQuillan, MD General Medicine Timothy T Nostrant, MD Gastroenterology Initial
More informationThe hidden endoscopic burden of sleeve gastrectomy and its comparison with Roux-en-Y gastric bypass
ORIGINAL ARTICLE Annals of Gastroenterology (2015) 28, 1-6 The hidden endoscopic burden of sleeve gastrectomy and its comparison with Roux-en-Y gastric bypass Katherine Arndtz a, Helen Steed b, James Hodson
More informationImproving Urgent and Emergency care through better use of pharmacists. Introduction. Recommendations. Shaping pharmacy for the future
Improving Urgent and Emergency care through better use of pharmacists The Royal Pharmaceutical Society (RPS) believes that pharmacists are an underutilised resource in the delivery of better urgent and
More informationMedication Management Improvement System Protocol #4 Potentially Inappropriate Use of NSAIDs
Medication Management Improvement System Protocol #4 Potentially Inappropriate Use of NSAIDs Problem: Use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) in clients with any one of the following risk
More informationIntroduction. Background to this event. Raising awareness 09/11/2015
Introduction Primary Care Medicines Governance HSCB Background to this event New class of medicines Availability of training Increasing volume of prescriptions Reports of medication incidents Raising awareness
More informationImproving the Value of an EAP Through a Coordinated Drug Intervention
It's all about employees; always has been, always will be. Improving the Value of an EAP Through a Coordinated Drug Intervention Presenters: Fred Newman Mike Hoffman What the Media are Reporting A significant
More informationClinical characteristics in patients with non-cardiac chest pain could favor gastroesophageal reflux disease diagnosis
Original article Annals of Gastroenterology (2013) 26, 1-5 Clinical characteristics in patients with non-cardiac chest pain could favor gastroesophageal reflux disease diagnosis Anastasios Karlaftis a,b,
More informationNash Heartburn Treatment Center
Nash Heartburn Treatment Center a division of Nash Health Care NHCS Mission Statement: To provide superior quality health care services and to help improve the health of the community in a caring, efficient
More informationPharmacists improving care in care homes
The Royal Pharmaceutical Society believes that better utilisation of pharmacists skills in care homes will bring significant benefits to care home residents, care homes providers and the NHS. Introduction
More informationSilent Reflux. Adult Speech & Language Therapy 01625 661067. Macclesfield District General Hospital. www.eastcheshire.nhs.uk
Silent Reflux Adult Speech & Language Therapy 01625 661067 Macclesfield District General Hospital www.eastcheshire.nhs.uk Leaflet Ref: 11067 Review: 11/2017 Page 1 Introduction Reflux is when acid stomach
More informationGastroesophageal Reflux Disease
Section Editors Christine Laine, MD, MPH David Goldmann, MD Science Writer Jennifer F. Wilson in the clinic Gastroesophageal Reflux Disease Diagnosis Treatment Practice Improvement CME Questions in the
More informationMedicare Part D Prescription Drug Coverage
Medicare Part D Prescription Drug Coverage Part 3 Version 7.1 August 1, 2013 Terms and Conditions This training program is protected under United States Copyright laws, 17 U.S.C.A. 101, et seq. and international
More informationPrescribing Framework for Donepezil in the Treatment and Management of Dementia
Hull & East Riding Prescribing Committee Prescribing Framework for Donepezil in the Treatment and Management of Dementia Patients Name:.. NHS Number: Patients Address:... (Use addressograph sticker) GP
More informationRevised M&M Conference Format into a Patient Safety M&M Leads to Performance Improvement Efforts in an Internal Medicine Department
Revised M&M Conference Format into a Patient Safety M&M Leads to Performance Improvement Efforts in an Internal Medicine Department Kevin C. Dellsperger, MD, PhD; Sue Scott, RN, MS (N); Matthew Bechtold,
More informationG E R D. (Gastroesophageal Reflux Disease)
G E R D (Gastroesophageal Reflux Disease) What is GERD? Gastroesophageal reflux disease (GERD) is a disorder caused by gastric acid flowing from the stomach into the esophagus. What are the symptoms of
More informationMedicare Appeals: Part D Drug Denials. December 16, 2014
Medicare Appeals: Part D Drug Denials December 16, 2014 2013 Appeals Statistics by Type 23,716 Part D Reconsideration Appeals* Appeals Type Percentage of Total Appeals Appeals Per Million Medicare Beneficiaries
More informationPediatric Gastroenterology Fellowship Pediatric Nutrition Rotation Goals and Objectives - 1 st Year
Pediatric Nutrition Rotation Goals and Objectives - 1 st Year Goal 1: Gain experience and competency in managing common and rare gastrointestinal, liver and nutritional problems. (Competencies: patient
More informationRe: CMS-1345-P; Medicare Program; Medicare Shared Savings Program: Accountable Care Organizations; Proposed Rule
Department of Health and Human Services Attention: CMS 1345 P P.O. Box 8013, Baltimore, MD 21244 8013 Re: CMS-1345-P; Medicare Program; Medicare Shared Savings Program: Accountable Care Organizations;
More informationExamination Content Blueprint
Examination Content Blueprint Overview The material on NCCPA s certification and recertification exams can be organized in two dimensions: (1) organ systems and the diseases, disorders and medical assessments
More informationSAMPLE ANTIMICROBIAL STEWARDSHIP POLICY
SAMPLE ANTIMICROBIAL STEWARDSHIP POLICY FOR A LOCAL HEALTH DISTRICT OR NETWORK Purpose of this document The development of an official policy for Antimicrobial Stewardship (AMS) is a fundamental step towards
More informationTreatment of Opioid Dependence: A Randomized Controlled Trial. Karen L. Sees, DO, Kevin L. Delucchi, PhD, Carmen Masson, PhD, Amy
Category: Heroin Title: Methadone Maintenance vs 180-Day psychosocially Enriched Detoxification for Treatment of Opioid Dependence: A Randomized Controlled Trial Authors: Karen L. Sees, DO, Kevin L. Delucchi,
More informationMEDICARE PRESCRIPTION DRUG PLANS: THE DEVIL IS IN THE DETAILS. Cori E. Uccello, FSA, MAAA, MPP Senior Health Fellow American Academy of Actuaries.
MEDICARE PRESCRIPTION DRUG PLANS: THE DEVIL IS IN THE DETAILS Cori E. Uccello, FSA, MAAA, MPP Senior Health Fellow American Academy of Actuaries and John M. Bertko, FSA, MAAA Member, American Academy of
More informationGUIDELINES FOR TUBERCULOSIS PREVENTIVE THERAPY AMONG HIV INFECTED INDIVIDUALS IN SOUTH AFRICA
GUIDELINES FOR TUBERCULOSIS PREVENTIVE THERAPY AMONG HIV INFECTED INDIVIDUALS IN SOUTH AFRICA 2010 1 TB prophylaxis GUIDELINES FOR TUBERCULOSIS PREVENTIVE THERAPY AMONG HIV INFECTED INDIVIDUALS Background
More informationTranslating Evidence to Safer Care Patient Safety Research Introductory Course Session 7 Albert W Wu, MD, MPH Former Senior Adviser, WHO Professor of Health Policy & Management, Johns Hopkins Bloomberg
More information2012 Vermont Household Health Insurance Survey: Comprehensive Report
Vermont Department of Financial Regulation Insurance Division 2012 Vermont Household Health Insurance Survey: Comprehensive Report Brian Robertson, Ph.D. Jason Maurice, Ph.D. Table of Contents Page I.
More informationWhat you should know about treating your pain with opioids. Important information on the safe use of opioid pain medicine.
What you should know about treating your pain with opioids Important information on the safe use of opioid pain medicine. If your healthcare provider has determined that opioid therapy is right for you,
More informationOmeprazole 20 mg gastro-resistant tablets PL 14017/0277
Omeprazole 20 mg gastro-resistant tablets PL 14017/0277 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific Discussion Page 4 Steps Taken for Assessment Page 11 Steps Taken After Initial Authorisation
More information